Free Trial

Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of "Hold" from Analysts

Novavax logo with Medical background
Remove Ads

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned an average recommendation of "Hold" from the seven ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.00.

NVAX has been the topic of several recent research reports. TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th.

Get Our Latest Stock Report on Novavax

Novavax Stock Up 2.1 %

Shares of Novavax stock traded up $0.17 on Friday, hitting $8.09. 2,005,260 shares of the company traded hands, compared to its average volume of 8,033,198. Novavax has a 12-month low of $3.81 and a 12-month high of $23.86. The company has a 50-day moving average price of $8.46 and a 200 day moving average price of $9.71. The company has a market cap of $1.30 billion, a PE ratio of -3.59, a PEG ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same period in the previous year, the company earned ($1.44) earnings per share. Equities research analysts anticipate that Novavax will post -1.46 EPS for the current year.

Remove Ads

Insiders Place Their Bets

In other news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James F. Young sold 5,400 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now owns 51,760 shares of the company's stock, valued at approximately $414,080. The trade was a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock valued at $119,641 in the last quarter. Insiders own 1.00% of the company's stock.

Institutional Trading of Novavax

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Novavax by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock valued at $126,439,000 after buying an additional 296,181 shares during the period. Shah Capital Management increased its position in shares of Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock valued at $89,637,000 after purchasing an additional 1,333,305 shares during the period. State Street Corp raised its stake in shares of Novavax by 26.7% in the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock valued at $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Sanofi bought a new position in Novavax in the fourth quarter worth $55,319,000. Finally, Geode Capital Management LLC boosted its stake in Novavax by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after buying an additional 155,206 shares in the last quarter. 53.04% of the stock is owned by institutional investors.

About Novavax

(Get Free Report

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Featured Articles

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Should You Invest $1,000 in Novavax Right Now?

Before you consider Novavax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.

While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads